More on NVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $150.20 |
|
|||
| Open | $150.20 | ||||
| 52 Wk High | $89.15 | ||||
| 52 Wk Low | $69.84 | ||||
| Day High | $150.20 | ||||
| Day Low | $150.20 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 6,660 | ||||
- Novartis ends mid-stage trial for Fabhalta in lupus nephritis
- FDA approves Novartis drug Rhapsido for symptomatic dermographism
- Novartis to present MS drug data at MSToronto2026 conference
- Novartis (NOVN:SW) (NVS) PT Lowered to CHF130 at Morgan Stanley
- EMA panel backs Novartis Cosentyx for rheumatic condition in EU
- Novartis halts ALS drug development after mid-stage trial fails
- Selloff in this biotech stock is overdone – Mizuho
- Novartis (NOVN:SW) (NVS) PT Lowered to CHF105 at Berenberg
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Entities mentioned with NVS
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
